Dr Sekeres on Luspatercept Plus Lenalidomide in Non–5q Deletion MDS

Mikkael A. Sekeres, MD, professor of medicine, chief, Division of Hematology, Leukemia Section, University of Miami Health System, Sylvester Comprehensive Cancer Center, discusses safety and efficacy results from a phase 1b/2 study (NCT04539236) combining luspatercept-aamt (Reblozyl) and lenalidomide (Revlimid) in patients with lower-risk, non–5q deletion myelodysplastic syndromes. Sekeres and colleagues shared these results in a presentation at the 2024 ASH Annual Meeting.